Hormone therapy was evaluated for noncardiovascular disease outcomes over 6.8 years in the HERS II trial, though specific results were omitted from the provided abstract.
Does Hormone Therapy (Estrogen/Progestin Replacement) affect Noncardiovascular Disease Outcomes over 6.8 years in participants of the Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II)?
Absolute Event Rate: 0% vs 0%
Hulley, Stephen; Furberg, Curt; Barrett-Connor, Elizabeth; Cauley, Jane; Grady, Deborah; Haskell, William; Knopp, Robert; Lowery, Maureen; Satterfield, Suzanne; Schrott, Helmut; Vittinghoff, Eric; Hunninghake, Donald for the HERS Research Group
Hulley et al. (Tue,) reported a other. Hormone therapy was evaluated for noncardiovascular disease outcomes over 6.8 years in the HERS II trial, though specific results were omitted from the provided abstract.